Cutting-Edge Research Programs Only Possible with Your Support
These innovative research projects will have a monumental impact in regard to the treatment and diagnosis of brain cancer. Your donation helps scientists and doctors study various approaches that can one day eradicate brain cancer.
Personalized Epigenetic Therapy For Treating Glioblastoma
Led by Jialiang Wang, PhD at Vanderbilt University
Netrin-1: Novel Non-Invasive Biomarker and Therapeutic Target For Pediatric Brain Tumors
Led by Edward Smith, MD at Boston Children’s Hospital
Eradicating Brain Cancer replica tag heuer carrera automatic black dial mens watch war211a ba0782 for sale Through Application of Cell-Penetrating Peptides Carrying Anti-Cancer Cargo
Led by James M. Angelastro at the University of California, Davis
Clinical Development of Type II EGFR Kinase Inhibitors for Glioblastoma
Led by Ingo K. Mellinghoff, MD at Memorial Sloaon-Kettering Cancer Center
Development of Glioblastoma Cancer Stem Cell Inhibitor
Led by Santosh Kesari, MD/PhD at the University of California, San Diego
Clinical development of a type II EGFR kinase inhibitor for glioblastomas
Led by Ingo K Mellinghoff, MD at Memorial Sloan Kettering Cancer
Multifunctional EGFR Targeting Nanovehicles for the Treatment of Brain Tumors
Led by Rolf Barth, MD at Ohio State University
Vaccination Against A Novel Survivan Epitope in Patients with Low Grade Glioma
Led by Hideho Okada, MD, PhD at the University of Pittsburgh Cancer Institute
Interleaved Carbon Ion Minibeams to Treat Dogs with Spontaneous Malignant Glioma
Led by F. Avraham Dilmanian, Ph.D. at Brookhaven National Lab
Characterizing the response of stem and progenitor like glioma cells to the chemoterhapeutic agent temozolomide
Led by Lindy Barrett, PhD at Memorial Sloan Kettering Cancer
Phase I Clinical Trial of the IGF-1R Inhibitor, AXL1717, for Treatment of Recurrent Malignant Astrocytomas
Led by Robert Aiken, MD at Rush University Medical Center
Whole Genome Sequencing of Pediatric Gangliogiomas
Led by Adam Resnick, Ph.D; Assistant Professor – Children’s Hospital of Philadelphia
Dissecting the role of cdk4 and cyclin D1 in glioma – therapeutic implications
Led by Andrew Koff at Memorial Sloan Kettering Cancer
Role of regulatory factor X1 in human gbm
Led by Zhiyi Zuo at University of Virginia
A radiation activated prodrug nanoparticle platform for brain cancer therapy
Led by Milan Theodore Makale at University of California, San Diego
Avoiding unnecessary toxicity and improving survival of children with low grade gliomas
Led by Simone zf rolex day date mens rolex calibre 2836 2813 118206 12mm 2 Treiger Sredni, MD PhD at Ann & Robert Lurie Children’s Hospital
Tackling resistance to Bevacizumab therapy in GBMs
Led by Gabriele Bergers at University of California, San Francisco
Preclinical evaluation of a Novel ERBB inhibitor optimized for CNS Biodistribution
Led by C. David James at University of California, San Francisco
Characterization of hnRNP A2/B1 as a new oncogen in glioblastoma and its inhibition as a new therapy
Led by Rotem Karni at Hadassah Medical School
Reprogramming iPSC Into Stem Cells, a possible turning point for cancer therapy
Led by Inan Olmez at Vanderbilt University Medical Center
Develop a tumor-suppressive, extracellular, protein (TSEP) to treat GBM
Led by Yi-Hong Zhou, PhD at The Regents of the University of California
Inhibitors of the PLD2-AKT signaling complex reveal a metabolic vulnerability in glioblastomas
Led by H Alex Brown at Vanderbilt University Medical Center
Proteasomal control of glioblastoma cancer stem cell function
Led by Albert Kim, MD PhD at Washington University School of Medicine
Intraarterial delivery to the glioma stem cell niche
Led by John Boockvar, MD at Cornell University
Role of miRNA-451 in the hypoxia-induced pro-angiogenic response of glioblastoma
Led by David Zagzag, MD, PhD at New York University
Exosome therapy for brain tumors
Led by Xandra Breakefield, PhD at Harvard University
Toxicity Profiling: Creating Novel Paradigms to Personalize Cancer Treatment
Led by Michael Scheurer at Baylor College of Medicine
Investigating cellular microparticles as biomarkers for glioblastoma growth and treatment
Led by Glenn Lesser, MD at Wake Forest School of Medicine
Actively Personalized vaccines for newly diagnosed gbm patients
Led by Hideho Okada, MD, PhD at University Of Pittsburgh
Identification and molecular analysis of circulating brain tumor cells
Led by Brian Vala Nahed at Massachusetts General Hospital
Pre-clinical testing of bacteriolytic therapy for gbm
Led by Gregory J. Riggins, MD, PhD at Johns Hopkins University
Understanding the Multifaceted Role of the TNF-Alpha in Brain Tumors
Led by Ilan Volovitz at the The Tel-Aviv Sourasky Medical Center
Other:
Interrogation of the Glioblastoma Exome to Overcome Therapy Resistance
Led by Claudia Petritch, PhD at University of California, San Francisco
Comprehensive Characterization of the Anaplastic Meningioma Genome
Led by Rameen Beroukhim, M.D., Ph.D. at the Dana Farber Cancer Institute
Evaluating the Impact of Microenvironmental Elasticity on the Stem Cell Phenotype in Malignant Glioma
Led by Justin D. Lathia, Ph.D. at the Cleveland Clinic
Convection-Enhanced Delivery of Ultrasmall nanoparticles loaded with Novel Drugs for Glioblastoma
Led by Jiangbing Zhou at the Yale University
Carboplatin Phase I Clinical Trials
Led by J. Bradley Elder, MD at the Department of Neurological Surgery at the Ohio State University Medical Center
Microglia in Glioblastoma Invasion
Led by Marc Symons, PhD at the Center for Oncology and Cell Biology at The Feinstein Institute for Medical Research
Personalized GBM Therapy using Notch and Akt Inhibition
Led by Xing Fan, MD PhD at the Department of Neurology at Regents of the University of Michigan
Genetic Marker Clinical Trials
Led by Tracy Batchelor, MD, MPH at Massachusetts General Hospital/Harvard Medical School
Stem Cell Neuro-Regeneration
Led by Henry Friedman, MD at Duke University Medical Center
T-Cell Immunotherapy
Led by Laura Johnson, PhD at Duke University Medical Center
Glioma Cell Migration and Invasion
Led by Steven Rosenfeld, MD, PhD at New York-Presbyterian Hospital/Columbia University Medical Center
Nanoparticle-Based Therapy
Led by Joseph Piepmeier, MD at Yale School of Medicine
Drug Clinical Trials
Led by Andrew B. Lassman, MD at Memorial Sloan-Kettering Cancer Center
Chemotherapy Coils
Led by Susan C. Pannullo, MD at New York-Presbyterian Hospital/Weill Cornell Medical Center
Young Investigators
Led by Dr. Jeffrey Raizer and Dr. Marcus Bredel at Northwestern University
Clinical Trials
Led by Steven S. Rosenfeld, MD, PhD at New York-Presbyterian Hospital/Columbia University’s Brain Tumor Center